Xenon Seven

Xenon Seven

Director, HCP Marketing

Boston · Director

Sponsorship not specified$25k-$40kDetected 8 days ago
RESTBrand StrategyVendor ManagementClinical TrialsFDA RegulatoryLeadershipCommunication

About the role

  • This role sits within US HCP Marketing and is responsible for delivering high-impact, compliant educational initiatives that improve disease understanding, clinical practice, and confidence in product use.
  • The Director will play a pivotal role in ensuring education is not only scientifically rigorous but also strategically differentiated-driving meaningful impact for both patients and the brand.
  • This position reports to the Senior Director, HCP Marketing, and will be based out of Boston, MA, USA in our Needham office.

Responsibilities

  • Program Design & Execution

Requirements

  • Proven experience supporting product launches or major brand milestones
  • Ability to travel up to 25-40% (congresses, field engagement, training programs)
  • Bachelor's degree required; advanced degree preferred
  • 10+ years of relevant management experience or combination of degrees and experience including 3-5+ years in HCP marketing, professional education, or medical education roles
  • Strong cross-functional leadership in a matrixed environment
  • Deep expertise in HCP engagement and education strategy
  • Strong brand and commercial acumen (especially in launch environments)
  • Understanding of compliance and regulatory requirements (FDA, PhRMA, ACCME as applicable)
  • Exceptional communication, storytelling, and influence skills
  • Data-driven decision-making and performance tracking
  • Ability to manage multiple priorities in a fast-paced environment

Nice to have

  • Bachelor's degree required
  • advanced degree preferred

Compensation

  • Our Total Rewards program includes base salary, target bonus, and stock options, as well as a full range of benefits including medical, dental, vision, short-& long-term disability, accidental death & dismemberment, and life insurance progr

Benefits

  • HCP Education Strategy (Brand & Launch Focus)
  • Lead the development of the US HCP education strategy aligned to brand goals, lifecycle stage (including launch-readiness), and key customer segments.
  • Translate brand strategy, positioning, and customer insights into actionable, differentiated education plans.
  • Identify priority HCP segments (specialists, community providers, advanced practice providers, etc.) and tailor education approaches accordingly.
  • Serve as the education lead in brand planning, ensuring strong integration across omnichannel touchpoints.
  • Oversee the design and execution of HCP education programs, including:
  • Congress strategy and educational presence
  • Digital and on-demand learning platforms
  • Develop compelling, insight-driven educational content aligned to clinical data and brand narrative.

Company info

  • Xenon Pharmaceuticals (NASDAQ:XENE https://www.nasdaq.com/market-activity/stocks/xene) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. We are looking for great people who thrive in a respectful, collaborative, inclusive, and productive culture to join the Xenon team.
  • What We Do:
  • We are advancing an exciting product pipeline https://xenon-pharma.com/pipeline to address indications with high unmet medical need, including epilepsy, depression and pain. Our Phase 3 azetukalner program represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. In March 2026, we announced positive topline data from our Phase 3 X-TOLE2 study of azetukalner in focal onset seizures (FOS), and we anticipate submitting a New Drug Application to the Food and Drug Administration in the third quarter of 2026. Our Phase 3 epilepsy program also includes a second FOS study, X-TOLE3, which would support regulatory submissions outside the U.S., and the X-ACKT study in primary generalized tonic-clonic seizures, which would support regulatory submissions for an additional epilepsy indication. We also have multiple Phase 3 azetukalner clinical trials underway in major depressive disorder (MDD) and bipolar depression (BPD), based on topline data from our Phase 2 X-NOVA clinical trial. In addition, we are proud of our strong heritage in human genetics, deep understanding of ion channel biology, and expertise in novel chemistries to enable potent, selective ion channel targeting. We continue to advance an early-stage pipeline of novel therapeutic candidates, including Phase 1 studies for XEN1701 (targeting Nav1.7) and XEN1120 (targeting Kv7), which are important pain targets. Backed by a strong balance sheet to support our growth plans, we continue to build a fully integrated, premier neuroscience company with strong discovery, clinical development, corporate, and commercial operations.
  • Xenon Pharmaceuticals (NASDAQ:XENE https://www.nasdaq.com/market-activity/stocks/xene) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need.
  • We are looking for great people who thrive in a respectful, collaborative, inclusive, and productive culture to join the Xenon team.
  • We are advancing an exciting product pipeline https://xenon-pharma.com/pipeline to address indications with high unmet medical need, including epilepsy, depression and pain.
  • Our Phase 3 azetukalner program represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications.
  • In March 2026, we announced positive topline data from our Phase 3 X-TOLE2 study of azetukalner in focal onset seizures (FOS), and we anticipate submitting a New Drug Application to the Food and Drug Administration in the third quarter of 2026.
  • Our Phase 3 epilepsy program also includes a second FOS study, X-TOLE3, which would support regulatory submissions outside the U.S., and the X-ACKT study in primary generalized tonic-clonic seizures, which would support regulatory submissions for an additional epilepsy indication.
  • We also have multiple Phase 3 azetukalner clinical trials underway in major depressive disorder (MDD) and bipolar depression (BPD), based on topline data from our Phase 2 X-NOVA clinical trial.
  • In addition, we are proud of our strong heritage in human genetics, deep understanding of ion channel biology, and expertise in novel chemistries to enable potent, selective ion channel targeting.
  • We continue to advance an early-stage pipeline of novel therapeutic candidates, including Phase 1 studies for XEN1701 (targeting Nav1.7) and XEN1120 (targeting Kv7), which are important pain targets.
  • Backed by a strong balance sheet to support our growth plans, we continue to build a fully integrated, premier neuroscience company with strong discovery, clinical development, corporate, and commercial operations.
Apply directly at Xenon Seven →Create a free account for alerts like thisView Xenon Seven immigration profile

This listing is sourced directly from Xenon Seven's careers page and normalized into a canonical job model.